



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

NOV 5 2013

Joy J. Liu  
Ropes & Gray, LLP  
One Metro Center, Suite 900  
700 12<sup>th</sup> Street, N.W.  
Washington, D.C. 20005-3948


Re: Docket No. FDA-2013-P-0608<sup>1</sup>

Dear Ms. Liu:

I am writing to inform you that the Food and Drug Administration (FDA) has not yet resolved the issues raised in your citizen petition received on May 9, 2013. Your petition requests that FDA adopt and apply certain bioequivalence requirements in its review of applications for generic versions of Invega Sustenna (paliperidone palmitate).

FDA has been unable to reach a decision on your petition because of the need to address other Agency priorities. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as possible given the numerous demands on the Agency's resources.

Sincerely yours,

  
for Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

---

<sup>1</sup> In your letter, you reference docket number FDA-2007-D-0369, which was the docket number erroneously assigned to your petition. Please note that the correct docket number is FDA-2013-P-0608